Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Germany
  4. Xetra
  5. Gerresheimer AG
  6. News
  7. Summary
    GXI   DE000A0LD6E6

GERRESHEIMER AG

(GXI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Gerresheimer at CPhI North America: Innovative packaging and easy administration of medications

07/28/2021 | 04:03am EDT
Gerresheimer produces numerous products for the pharma world in cleanroom environments.

Düsseldorf/Philadelphia, July 28, 2021. When it comes to packaging, safely storing and administering medications, biologics, and vaccines simply and sustainably, Gerresheimer is always a good address and an accomplished partner in the American market. At CphI North America from August 10-12, the company will be exhibiting primary packaging such as injection vials and other containers made of glass and plastic for solid and liquid medications as well as syringes which protect against needlestick injuries at booth 1313 in the Pennsylvania Convention Center in Philadelphia.

Best in class - Gx Elite Vials set a new standard
The Gx Elite vials are the result of a careful product development process spanning several years. The primary focus for was to provide a Type I vial made of borosilicate glass that would be a safer product for the customer and the patient. The highly shatter-resistant vials are extremely durable, free of cosmetic defects and can be customized for specialized customer requirements. Gx Elite Glass vials are produced using the quality by design (QbD) approach that creates a product that will exceed customers' expectations. A combination of design, manufacturing, and handling improvements along with specialized final packaging also ensures that the vials can be supplied for end-to-end use on various filling lines. These types of improvements make it possible for our customers to supply products to the market as needed and reduce costs for the industry, which will ultimately help everyone. Gx Elite vials, which meet all existing regulatory requirements worldwide, are also available in RTF (ready-to-fill) format.

Ready for filling - Gx RTF Vials for clinical trials
The Gx RTF injection vials are made of borosilicate glass type I and meet all common requirements of the applicable ISO standards and pharmacopoeias (USP and Ph. Eur.). They are formed in accordance with cGMP, washed in a clean room, packaged in trays or nests and tubs and sterilized. Gerresheimer RTF vials are also supplied in the familiar Ompi EZ-fill or any other packaging format. This means they are ready for the next process steps in filling. The advantages are obvious: sterile delivery, a simplified filling and finishing process, the highest quality standards, flexibility thanks to various packaging configurations and a wide range of filling and sealing technologies. This all adds up to an improvement in overall manufacturing costs over the product life cycle.

For your eyes only - Dropper bottle systems for ophthalmic drugs
Often it is only the small improvements that make a product ideal for the application. The design was developed specifically for the US market. Many people must take eye drops several times a day, so it is important that these bottles work reliably until the last drop. One example is the new dropper bottle system E / F with different closure solutions - a closure where the tamper-evident ring (TE) remains attached to the bottle after opening (system E) and a sleeved cap (system F). They can be supplied already sterilized (gamma irradiated) or packaged for sterilization only.

RTU COP Vials for injectable and diagnostic products
RTU COP (Cyclic Olefin Polymer) vials combine the best features of plastic and glass packaging for liquid drugs. With their high break strength, inert resin material and high transparency, they are an ideal packaging solution for cell and gene therapy products. The vials offer an inert contact surface and have been proven in various pharmaceutical applications in the market. They also provide manufacturers of toxic or high potency drug solutions with a unique packaging safety feature. The monolayer plastic vials are offered in a standard ISO-like format in 2-, 5-, 10-, 50- and 100-ml sizes.

Gx InnoSafe: More safety from needlestick injuries
With their exposed needles, used syringes are an omnipresent source of danger in doctors' surgeries, laboratories and hospitals. With Gx InnoSafe, Gerresheimer now offers a syringe with an integrated, passive safety system which prevents unintentional needle-stick injuries.

Gx RTF ClearJect: Gerresheimer produces COP syringes in Germany
Gerresheimer presents its newly developed Gx RTF ClearJect brand: a COP syringe with cannula. The prefillable syringes are produced at the German plant in Pfreimd from the high-performance plastic COP (cyclo-olefin polymer) and are particularly suitable for sophisticated, sensitive medications and high-viscosity active ingredients.

Gerresheimer locations in North America and Mexico
Gerresheimer produces glass and plastic containers for the pharma industry in North America and Mexico at the following production sites:

Glass Innovation Center, Vineland, New Jersey
The technical center of excellence develops innovative solutions in primary packaging glass, technologies and digitized processes to meet evolving demand of the pharmaceutical industry.

Gerresheimer Glass Inc, Vineland Plant, New Jersey
The Vineland plant produces Type I glass products, in both clear and amber. These products include dental and pharmaceutical cartridges, insulin pen cartridges, specialty and pharmaceutical vials, syringes and innovative technology.

Gerresheimer Glass Inc, Chicago Heights Plant, Illinois
Containers made of type I clear glass are produced here. The product range includes serum bottles, bottles with screw caps, IV bottles and various other bottles made of container glass.

Gerresheimer Glass Inc, Morganton Plant, North Carolina
The Morganton plant produces serum vials, large outer diameter vials, and double chamber vials in Type I glass in clear and amber.

Gerresheimer Glass Inc., Forest Grove Plant/Vineland, New Jersey
Type I glass pharmaceutical containers in clear and amber are produced here. These are serum vials, vials with large outer diameter, vials for rapid cultivation, special vials and cartridges.

Gerresheimer Querétaro S.A., Mexico
The Mexican plant produces ampoules, serum vials, screw-cap vials, ADD vantage vials, RTF syringes and vials, cartridges, onion skin tubes and specialty products from Type I clear and amber glass and Type III amber glass.

Centor Inc, Berlin Plant, Perrysburg, Ohio
Centor has been part of the Gerresheimer Group since 2015 and is a leading manufacturer of plastic containers for prescription medicines that meet regulatory requirements in the US end-customer market. Centor supplies nationwide and regional pharmacy chains, supermarkets and wholesalers.

Gerresheimer Primary Packaging Plastic, Berlin, Ohio
Since May 2018, Gerresheimer Primary Packaging Plastic has been producing HDPE containers for tablets under cleanroom conditions in accordance with FDA regulations at the Centor Berlin plant. A new building to produce plastic containers for the pharma industry is currently being built here with class 8 cleanrooms on an area of around 6,000 square meters.

Gerresheimer Peachtree City, Medical Systems, Georgia
At the site in Peachtree City near Atlanta (Georgia), founded in 1993, customer-specific inhalers, test cards for microbiological test systems, various components for insulin delivery devices and closures for ampoules are produced.

Gx®, Innosafe® and RTF® are registered trademarks of the Gerresheimer Group. Ompi EZ-fill® is a registered trademark of Ompi, a trademark of the Stevanato Group.

Pharmaceutical primary packaging from Gerresheimer

About Gerresheimer

Gerresheimer is a leading global partner to the pharma and healthcare industry. With specialty products made of glass and plastic, the company contributes to health and well-being. Gerresheimer is represented worldwide and produces with around 10,000 employees wherever its customers and markets are. With plants in Europe, North and South America and Asia, Gerresheimer generates sales of around €1.4 billion. Its wide range of products includes ¬pharmaceutical packaging and products for the simple and safe administration of medicines: Insulin pens, inhalers, micropumps, prefillable syringes, injection vials, ampoules, bottles, and containers for liquid and solid medications with closure and safety systems as well as packaging for the cosmetics industry.

Disclaimer

Gerresheimer AG published this content on 28 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 July 2021 08:02:04 UTC.


© Publicnow 2021
All news about GERRESHEIMER AG
09/17GERRESHEIMER AG : Deutsche Bank reaffirms its Buy rating
MD
09/13GERRESHEIMER : plans to use the latest technology for greater sustainability in ..
PU
09/09CONTINUITY ON THE MANAGEMENT BOARD : Gerresheimer extends contract with CFO Dr. ..
PU
09/09GERRESHEIMER AG : Continuity on the Management Board: Gerresheimer extends contr..
EQ
09/09PRESS RELEASE : Gerresheimer AG: Continuity on the Management Board: Gerresheime..
DJ
09/02GERRESHEIMER : The new Gerresheimer Cosmetic World has launched
PU
08/18GERRESHEIMER : produces sustainable flacons for Oriflames' new Swedish Experienc..
PU
08/11GERRESHEIMER AG : Goldman Sachs remains its Buy rating
MD
08/10GERRESHEIMER : CSR audit confirms Gerresheimer's strong success in its sustainab..
PU
07/28GERRESHEIMER AT CPHI NORTH AMERICA : Innovative packaging and easy administratio..
PU
More news
Analyst Recommendations on GERRESHEIMER AG
More recommendations
Financials
Sales 2021 1 470 M 1 724 M 1 724 M
Net income 2021 107 M 126 M 126 M
Net Debt 2021 970 M 1 138 M 1 138 M
P/E ratio 2021 24,8x
Yield 2021 1,54%
Capitalization 2 658 M 3 120 M 3 117 M
EV / Sales 2021 2,47x
EV / Sales 2022 2,30x
Nbr of Employees 10 032
Free-Float 100%
Chart GERRESHEIMER AG
Duration : Period :
Gerresheimer AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GERRESHEIMER AG
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 84,65 €
Average target price 102,01 €
Spread / Average Target 20,5%
EPS Revisions
Managers and Directors
Dietmar Siemssen Chief Executive Officer
Bernd Metzner Chief Financial Officer
Axel Herberg Chairman-Supervisory Board
Theodor Stuth Member-Supervisory Board
Udo Johannes Vetter Member-Supervisory Board
Sector and Competitors
1st jan.Capi. (M$)
GERRESHEIMER AG-3.53%3 120
ABBOTT LABORATORIES15.80%224 776
MEDTRONIC PLC10.72%174 552
BECTON, DICKINSON AND COMPANY4.69%75 229
HOYA CORPORATION30.10%62 323
ALIGN TECHNOLOGY, INC.34.62%56 839